Main

Intellectual Property Archives

September 17, 2007

Not soft on Microsoft

I suppose everyone is fascinated by whatever aspect of the Microsoft/EU antitrust case validate their political ideas. For many people, it is the triumph of the state against the big, bad corporation; for others, it is an unwarranted intrusion into free markets. Here are the aspects that interest me, though:

  1. Antitrust lags the market in a way that threatens to make it meaningless. Just as the IBM antitrust case was quickly made irrelevant by the shift of market power from hardware to software, the EU has come in to force open a market that no longer seems either so important, or so thoroughly dominated by Microsoft. Now Apple and Google are the rising threats, and undoubtedly, in a decade they too will be under fire from some firm you've probably never heard of. In the future, we may see antitrust rulings coming just in time for the bankruptcy sale.


  2. The EU regulatory commission seems notably more hostile to American companies than to locals. If EU antitrust authorities come to be seen as having a mandate to force European products on unwilling consumers, they will do a great deal of damage to both European markets, and world trade.


  3. Many of the EU's supporters on this are hoping that the union will become a defacto super-regulator, which can use its market size to force changes on international companies. Henry Farrell writes:
    It is possible for companies such as Microsoft to sell different products in the EU and the US. But it is very expensive to have to do this, as well as often being politically awkward (when consumers would like what is on offer in another jurisdiction but can’t get it), and always organizationally highly inconvenient. The result is that companies are likely to make their products comply with EU rules across markets, except when the costs to so doing are very high indeed. This means that the European Commission is effectively becoming a regulator that substantially affects what is or isn’t sold in US markets too. The US administration has taken a hands-off (some might say supine) approach to preventing monopoly abuses in technology markets – the Commission is now in an excellent position to start to fill this regulatory vacuum. This should make for some interesting politics – while the US administration is likely to deplore this ruling, I don’t know that there is very much that it can actually do about it (especially given the continued controversy over its decision to roll over for Microsoft after the Bush administration came into office). It seems to me that the Commission has chosen its case very well, with respect to cementing its power over European information technology markets and increasing its international influence very substantially too. This should make for very interesting international politics.

    Certainly, there was a substantial forum-shopping aspect to this case; technology companies that couldn't compete in the US ran to friendlier European regulatory agencies with their complaints. There is no logical reason that competitive frictions between Real Networks, Sun Microsystems, or Novell, and Microsoft, should have been adjudicated in Europe.

    But Henry's optimism assumes that the effect of the regulatory breakup is to make consumers (rather than producers) better off. This seems a rather dubious assumption considering that it's major achievement so far has been forcing Microsoft to sell its software with fewer features at the same price as the fuller-featured product. Had the commission gone farther, and forced the company simply to entirely unbundle Windows Media Player, the result would have been to advantage Real, but deprive consumers of something they had been getting for free.

    Perhaps Microsoft will harmonize its versions. Or perhaps it will sell a dumbed down European version at the same price as the full-featured US product, while loudly announcing that they are doing so in response to EU antitrust regulations. Perhaps consumers will still get mad at Microsoft, instead of the commission. But I wouldn't count on it. This sort of political consideration will considerably constrain the commission's power. It will even do so for "invisible" changes, such as the efforts to get Microsoft to disclose its server hooks. Microsoft might just decide to keep Europe one version behind America, which would not bolster already weakening support for central EU regulation.

September 5, 2007

Harder than it looks

It's rather common to hear those in favor of price controls on prescription drugs argue that the government does all the real research anyway, and the pharmas just steal it and slap their name on the resulting pill; or that the cost of R&D is wildly overblown.

As a counterexample to these two claims, I (well, Derek Lowe, really) give you: Renin inhibitors.

I notice that the first marketed renin inhibitor seems to be doing fairly well. That's an interesting phrase, "first marketed renin inhibitor". . .

This is a good example of what drug discovery can be like. Renin is a fine drug target – it’s been known for a long time as a key component of blood pressure regulation, and that’s a condition affecting a huge market whose treatment provides a real medical benefit. What more do you want?

OK, let’s make it even more attractive. It’s not that hard to set up a renin assay, and the protein is well-studied. The counterscreens and secondary assays are not a problem; hypertension is fairly well understood. And if you screen for renin inhibitors, you generally find chemical matter to start off with, too. Protease inhibitors vary quite a bit in their drug-likeness, but they’re certainly not impossible on the face of them.

But even after all this, I would not like to be asked to count how many renin inhibitors have been reported over the years, never to be seen again. The first reports I can find go back to the early 1980s. Given the lead time for these things, I can safely assume that these compounds were being made around the time I went the my high school Junior Prom (theme: “Saturday Night Fever”, natch – it was 1978, after all). And here we are in 2007, and the first one has finally made it to market. It wasn't easy, either - the compound was left for dead years ago, and was only kept going by some ex-Novartis people who started their own company and licensed the compound back to Novartis when it finally made it through the rough spots.

So, what’s the problem? Many compounds have been done in by poor behavior in living models (distribution, absorption, and so on). Getting oral bioavailability in this area has been a lot harder than anyone thought, and even the current drug is no great winner in that category. Projects start and stop, difficulties occur, and the years go by. And other mechanisms for going after hypertension have, of course, come to market, starting with the ACE inhibitors (which come from roughly the same disco era as the first run of renin compounds). They took the gigantic market that an early-1980s renin inhibitor would have had, but even so, I don’t think a year has gone by since that someone in the industry hasn’t been working on one. (There's still room to think that a renin compound would have a better profile than the existing drugs, though). And here we are: 2007. A sobering thought, that is.

August 25, 2007

Lock-in

Apparently it has taken all of two months for people to figure out how to unlock the iPhone. I find it hard to imagine that this will make a dent in Cingular's profits--the majority of people aren't going to mess around with soldering guns and cards. On the other hand, I imagine people said the same thing about that crazy Napster network.


Copyright © 2007 by The Atlantic Monthly Group. All rights reserved.